Continuous Cancer Monitoring with AI With: Dr. Azra Raza
Dr. Azra Raza, Professor of Medicine at Columbia University, argues that stage one cancer detection is already too late. She critiques current screening methods—which generate millions of false positives and cost billions annually—and advocates for continuous health monitoring from birth. Raza envisions implantable stents equipped with sensors and chips that can detect abnormal cells in real time, transmitting alerts to a patient’s phone. Coupled with AI and machine learning, this approach could enable detection at the 'first cell stage,' revolutionizing cancer prevention and patient outcomes.
Episode Contents:
About the Guest
Dr. Azra Raza is a Professor of Medicine at Columbia University and a leading oncologist advocating for early cancer detection through continuous monitoring. Learn more at: https://en.wikipedia.org/wiki/Azra_Raza
Key Takeaways
- Current cancer screening produces millions of false positives yearly.
- Continuous monitoring from birth could detect cancer before stage one.
- AI and implantable devices may enable 24/7 health surveillance.
Transcript Summary
Why is longitudinal data important in cancer detection?
Current screening for five major cancers produces 8.8 million false positives annually, costing B. Continuous monitoring could catch cancer before stage one.
What technology could enable this?
Implantable stents with sensors could detect abnormal cells in real time and send alerts via a connected app.
How can AI improve this?
AI and machine learning can rapidly distinguish between malignant and benign signals, enabling detection at the 'first cell stage' before traditional symptoms.
More Topics
- AI in Patient Care
- AI in the Healthcare Industry
- AI and Medical Innovation
- Healthcare Ethics and Policy
Keep Exploring
About the Series
AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine.
Dr. Sanjay Juneja, a hematologist and medical oncologist widely recognized as “TheOncDoc,” is a trailblazer in healthcare innovation and a rising authority on the transformative role of AI in medicine.
Mika Newton is an expert in healthcare data management, with a focus on data completeness and universality. Mika is on the editorial board of AI in Precision Oncology and is no stranger to bringing transformative technologies to market and fostering innovation.